Sirnaomics Announces Interim Data from Phase I Clinical Trial of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors
- Written by PR Newswire
First three out of five cohorts pass safety requirements, allowing the Company to dose additional cohorts to assess safety, tolerability, pharmacokinetics and anti-tumor activity
HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Dec. 21, 2022 /PRNewswire/ -- Sirnaomics Ltd. (Stock Code: 2257.HK) (the "Company", together with its subsidiaries, "Sirnaomi...














